Gradalis is dedicated to developing and commercializing “molecular” based personalized therapeutics that are tumor specific, more effective and less toxic than current treatment modalities.

Gradalis Announces a Novel Combination Study of Vigil® EATC Gradalis Announces a Novel Combination Study of Vigil® EATC
Gradalis Announces Research Alliance with Mount Sinai Gradalis Announces Research Alliance with Mount Sinai
Gradalis to Present at Biotech Showcase Gradalis to Present at Biotech Showcase 2017 Conference
A Statement From Gradalis A Statement Regarding Ewing's Sarcoma Trial
Dr. Brian Daniels joins the SAB Gradalis Announces the Appointment of Dr. Brian Daniels to the Newly Formed Scientific Advisory Board
Dr. Steven Burakoff Joins Gradalis SAB Appointment of Dr. Steven Burakoff to the Gradalis Scientific Advisory Board
Gradalis to Participate in iC3 Life Science Summit Gradalis to Participate in 2nd Annual iC3 Life Science Summit Hosted By BioNorthTX
Bio Investor Forum Press Release Gradalis to Take Part in BIO Investor Forum in San Francisco
SAB Formation Press Release Sir Marc Feldmann to Chair Gradalis Scientific Advisory Board
Vigil®
Immunotherapies
Goal